Related Experiment Videos
Combination therapy of pions and SPG (Sonifilan, Schizophyllan), a biological response modifier for mouse tumor
Y Ogawa1, G B Goodman, D J Chaplin
1Developmental Radiotherapy, Cancer Control Agency of British Columbia, Vancouver, Canada.
Abstract:
Female C3H mice aged 8-10 weeks with transplanted KHT sarcoma or SCCVII tumor were used to investigate the antitumor effect of SPG (Sonifilan, Schizophyllan) alone and in combination with local irradiation of pions with 4 fractions of 400 cGy (total 1600 cGy). Daily doses of 10 mg/kg of SPG were given intramuscularly to the mice bearing KHT sarcoma for 14 consecutive days from day 7, and to mice bearing SCCVII tumor for 20 consecutive days from day 7 and thereafter three times a week for another 2 weeks. The antitumor effect was evaluated by the changes in tumor volume, survival curves, and the number of pulmonary metastatic nodules on the surface of the lungs. SPG failed to exert any antitumor effect and any life-prolonging effect for the KHT sarcoma. As for SCCVII tumor, in the group treated with pions and SPG, tumor growth decreased significantly (p less than 0.01) compared with the group treated with pion only, and life prolonging effect and metastasis-suppressing effect were also observed (p less than 0.04). In conditions of minimal residual disease brought about by pion irradiation, the adjuvant effect of a Biological Response Modifier (BRM) SPG may prove to be a promising method of cancer therapy for some tumors.
Insights
Sonifilan (SPG) showed no antitumor effect against KHT sarcoma in mice. However, SPG combined with pion irradiation significantly inhibited SCCVII tumor growth and metastasis.
Area of Science:
- Oncology
- Immunology
- Radiotherapy
Background:
- Sonifilan (SPG), a Biological Response Modifier (BRM), is investigated for its therapeutic potential.
- Pion irradiation is a localized radiotherapy technique used in cancer treatment.
Purpose of the Study:
- To evaluate the antitumor effects of Sonifilan (SPG) alone and in combination with pion irradiation.
- To assess the impact on tumor volume, survival rates, and pulmonary metastasis in KHT sarcoma and SCCVII tumor models.
Main Methods:
- Female C3H mice bearing KHT sarcoma or SCCVII tumors were used.
- SPG was administered daily at 10 mg/kg, with specific durations for each tumor type.
- Tumors were treated with local pion irradiation (4 fractions of 400 cGy).
- Antitumor effects were measured by tumor volume, survival curves, and metastatic nodule counts.
Main Results:
- SPG alone demonstrated no significant antitumor or life-prolonging effects on KHT sarcoma.
- Combination therapy with pions and SPG significantly reduced SCCVII tumor growth (p < 0.01).
- SPG combined with pion irradiation also showed a significant life-prolonging effect and suppressed metastasis in SCCVII tumors (p < 0.04).
Conclusions:
- SPG is ineffective as a standalone treatment for KHT sarcoma.
- SPG may act as a promising adjuvant therapy when combined with pion irradiation for specific tumors like SCCVII, particularly in minimizing residual disease.
- This combination therapy warrants further investigation for its potential in cancer treatment.